Federated Hermes Inc. Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Federated Hermes Inc. lifted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 633,663 shares of the medical research company's stock after acquiring an additional 64,750 shares during the quarter. Federated Hermes Inc. owned 0.48% of Natera worth $100,309,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NTRA. Wilmington Savings Fund Society FSB purchased a new position in Natera in the 3rd quarter worth about $385,000. Everence Capital Management Inc. bought a new stake in Natera during the 4th quarter valued at $573,000. Smartleaf Asset Management LLC lifted its holdings in shares of Natera by 50.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock worth $104,000 after buying an additional 220 shares during the period. SeaBridge Investment Advisors LLC purchased a new position in shares of Natera during the fourth quarter valued at $2,894,000. Finally, SYM FINANCIAL Corp bought a new stake in shares of Natera in the fourth quarter valued at about $256,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 3.3 %

Shares of NTRA traded up $4.76 during midday trading on Friday, reaching $148.04. The company had a trading volume of 1,364,917 shares, compared to its average volume of 1,394,665. The firm has a 50 day simple moving average of $152.66 and a 200-day simple moving average of $152.05. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $20.01 billion, a PE ratio of -84.11 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NTRA. Morgan Stanley lifted their price target on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada started coverage on shares of Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. The Goldman Sachs Group boosted their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. Finally, Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.76.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00. Following the sale, the insider now owns 141,782 shares in the company, valued at $19,917,535.36. This represents a 2.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John Fesko sold 663 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,922 shares of company stock worth $51,603,664 over the last quarter. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.